These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 14718694)

  • 1. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
    Ondo WG; Hunter C; Moore W
    Neurology; 2004 Jan; 62(1):37-40. PubMed ID: 14718694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drooling in Parkinson's disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins.
    Narayanaswami P; Geisbush T; Tarulli A; Raynor E; Gautam S; Tarsy D; Gronseth G
    Parkinsonism Relat Disord; 2016 Sep; 30():73-7. PubMed ID: 27406786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
    Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
    Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease.
    Guidubaldi A; Fasano A; Ialongo T; Piano C; Pompili M; Mascianà R; Siciliani L; Sabatelli M; Bentivoglio AR
    Mov Disord; 2011 Feb; 26(2):313-9. PubMed ID: 21259343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.
    Mancini F; Zangaglia R; Cristina S; Sommaruga MG; Martignoni E; Nappi G; Pacchetti C
    Mov Disord; 2003 Jun; 18(6):685-8. PubMed ID: 12784273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    J Neurol; 2009 Apr; 256(4):563-7. PubMed ID: 19401804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea.
    Steinlechner S; Klein C; Moser A; Lencer R; Hagenah J
    Psychopharmacology (Berl); 2010 Jan; 207(4):593-7. PubMed ID: 19823807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
    Egevad G; Petkova VY; Vilholm OJ
    J Parkinsons Dis; 2014; 4(3):321-6. PubMed ID: 24919823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B.
    Wilken B; Aslami B; Backes H
    Neuropediatrics; 2008 Aug; 39(4):200-4. PubMed ID: 19165707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin for treatment of parkinsonian sialorrhea.
    Friedman A; Potulska A
    Neurol Neurochir Pol; 2001; 35 Suppl 3():23-7. PubMed ID: 12001650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease.
    Dogu O; Apaydin D; Sevim S; Talas DU; Aral M
    Clin Neurol Neurosurg; 2004 Mar; 106(2):93-6. PubMed ID: 15003297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.
    Petracca M; Guidubaldi A; Ricciardi L; Ialongo T; Del Grande A; Mulas D; Di Stasio E; Bentivoglio AR
    Toxicon; 2015 Dec; 107(Pt A):129-40. PubMed ID: 26327120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of botulinum toxin A for treatment of drooling.
    Lipp A; Trottenberg T; Schink T; Kupsch A; Arnold G
    Neurology; 2003 Nov; 61(9):1279-81. PubMed ID: 14610139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin injections for children with excessive drooling.
    Hassin-Baer S; Scheuer E; Buchman AS; Jacobson I; Ben-Zeev B
    J Child Neurol; 2005 Feb; 20(2):120-3. PubMed ID: 15794177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin A as treatment for drooling saliva in PD.
    Pal PK; Calne DB; Calne S; Tsui JK
    Neurology; 2000 Jan; 54(1):244-7. PubMed ID: 10636161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: efficacy and possible mechanisms.
    Møller E; Karlsborg M; Bardow A; Lykkeaa J; Nissen FH; Bakke M
    Acta Odontol Scand; 2011 May; 69(3):151-7. PubMed ID: 21198339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial.
    Alrefai AH; Aburahma SK; Khader YS
    Clin Neurol Neurosurg; 2009 Jan; 111(1):79-82. PubMed ID: 18977585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.
    Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Dorsch U; Csikós J; Blitzer A
    Parkinsonism Relat Disord; 2020 Jan; 70():23-30. PubMed ID: 31794936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin-A injections vs radiotherapy for drooling in ALS.
    Weikamp JG; Schinagl DA; Verstappen CC; Schelhaas HJ; de Swart BJ; Kalf JG
    Acta Neurol Scand; 2016 Sep; 134(3):224-31. PubMed ID: 26803950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.